17.59
+0.28(+1.62%)
Currency In USD
| Previous Close | 17.31 |
| Open | 16.96 |
| Day High | 17.65 |
| Day Low | 16.62 |
| 52-Week High | 25.67 |
| 52-Week Low | 13.5 |
| Volume | 1.65M |
| Average Volume | 3.04M |
| Market Cap | 4.19B |
| PE | 20.45 |
| EPS | 0.86 |
| Moving Average 50 Days | 18.09 |
| Moving Average 200 Days | 18.09 |
| Change | 0.28 |
If you invested $1000 in ADMA Biologics, Inc. (ADMA) 10 years ago, it would be worth $2,931.67 as of January 21, 2026 at a share price of $17.59. Whereas If you bought $1000 worth of ADMA Biologics, Inc. (ADMA) shares 5 years ago, it would be worth $7,268.6 as of January 21, 2026 at a share price of $17.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated Year-End 2025 Cash Grew to Approximately $88 M
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical